Company Avanir Pharmaceuticals Inc
Equities
US05348P4019
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
2014 | Otsuka : Japan's Otsuka to buy Avanir for $3.5 billion ahead of patent cliff | RE |
2014 | NASDAQ OMX : names 14 stocks to test lower fee and rebate programme | RE |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Dan Dalton
CMP | Compliance Officer | - | 01/16/01 |
Kelly Parker
IRO | Public Communications Contact | - | 01/15/01 |
Aneta Ferguson
LAW | General Counsel | - | 01/15/01 |
Hisanori Maei
PRN | Corporate Officer/Principal | - | 13/15/13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Donald Hayden
CHM | Chairman | 68 | - |
Robert McQuade
BRD | Director/Board Member | 67 | - |
Thomas DesRosier
BRD | Director/Board Member | 69 | - |
Robert Sedor
BRD | Director/Board Member | - | 13/15/13 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 193,758,703 | 190,369,337 ( 98.25 %) | 0 | 98.25 % |
Company contact information
![address Avanir Pharmaceuticals Inc](https://cdn.zonebourse.com/static/address/16730.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+15.58% | 121B | |
+16.60% | 110B | |
+17.73% | 25.93B | |
-24.33% | 19.27B | |
-19.35% | 16.01B | |
-17.95% | 15.66B | |
-48.32% | 14.89B | |
+58.78% | 14.47B | |
+4.91% | 13.91B |
- Stock Market
- Equities
- Stock
- Company Avanir Pharmaceuticals Inc